The integrated analysis of two parallel Phase 3 studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD) was reported.
The patients treated with EYLEA for Intravitreal Injection showed a sustained improvement in visual acuity at 96 weeks versus baseline.
A generally favorable safety profile was observed for both EYLEA and ranibizumab.
The incidence of ocular treatment emergent adverse events was balanced across all treatment groups in both studies.
Regeneron chief scientific officer George Yancopoulos said that the second year results confirm the sustainability of the vision gains achieved by EYLEA with a less than monthly dosing frequency.
"Importantly, the second year data demonstrated that for patients that needed more anti-VEGF treatment, this was achieved with fewer injections using EYLEA," added Yancopoulos.